Selskabets formål er udvikling og fremstilling af samt handel med lægemidler og hertil beslægtede varer.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 58.6 mio. | 2.9 mio. | 107.7 mio. | 48.8 mio. | 67 | |
CVR: 41059044
Previous names: ApS STM nr. 6418, Dalmore Invest (Denmark) ApS, Orifarm Manufacturing Hobro ApS
1 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Thomas Hørslev Hedegaard left the board
Mads Fink Eriksen joined as ADM. DIR.
Thomas Hørslev Hedegaard left as ADM. DIR.
Nicki Lund Kristensen joined the board
companydata.dk